Anti-CD105 Antibody Formulations for Angiogenesis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer lack effective and non-toxic systemic therapies, and angiogenesis plays a critical role in cancer progression and metastasis, with existing therapies failing to adequately address the recruitment of new blood vessels for tumor growth and spread.
Innovation Solution
Development of new formulations of anti-CD105 antibodies, pre-filled syringes, and their use for intravenous or intraocular administration to target angiogenesis-related disorders, including cancers and ophthalmologic conditions, with formulations stabilized to maintain antibody activity and stability over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then tumor growth is targeted, but systemic toxicity and lack of effectiveness occur
Solution Approach 1:
The patent formulates anti-CD105 antibodies with specific local concentrations (1-150 mg/ml) and optimized pH conditions (4.0-7.5) to enhance therapeutic effectiveness at the tumor site while minimizing systemic toxicity through targeted angiogenesis inhibition
2Duration of action of stationary object
If anti-CD105 antibody formulations are stored long-term, then availability for treatment is improved, but antibody stability and activity may deteriorate
Solution Approach 1:
The patent optimizes formulation parameters including pH (4.0-7.5), buffering agent concentration (up to 100 mM), and polyol concentration (up to 1 M) to maintain antibody stability during long-term storage at 2-8°C for at least 12 months, ensuring at least 95% monomer integrity
Solution Approach 2:
The patent introduces buffering agents (histidine or phosphate buffered saline) and polyols as protective intermediaries that stabilize the anti-CD105 antibody structure during storage, preventing aggregation and degradation while maintaining biological activity
3Reliability
If high concentration antibody formulations are used, then treatment efficacy is improved, but formulation stability and handling difficulty increase
Solution Approach 1:
The patent develops formulations across a wide concentration range (1-150 mg/ml) with optimized pH (4.0-7.5) and stabilizing excipients to maintain both high efficacy at elevated concentrations and manageable formulation complexity through systematic parameter optimization
Data Source
AI summary
The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.